LymphomaPhase 3NCT00075946
Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
A Phase 3 study testing rituximab in people with Lymphoma, run by Eastern Cooperative Oncology Group at 483 sites in United States.
Trial summary
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known which rituximab regimen is more effective in treating indolent non-Hodgkin's lymphoma. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lymphoma
- What is being tested?
- rituximab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 545 participants
- Where
- 483 sitesUnited States
- Study dates
- 23 Jan 2004to Aug 2021
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically confirmed non-Hodgkin's lymphoma, including 1 of the following:
- Follicular grade 1 or 2
- Small lymphocytic
- Marginal zone (nodal)
- Marginal zone (splenic)
- Mucosa-associated lymphoid tissue (MALT)
Show all 34Show fewer
- Stage III or IV disease
- Must meet the following criteria for low tumor burden:
- No nodal or extranodal mass at least 7 cm
- Less than 3 nodal masses greater than 3 cm in diameter
- No systemic symptoms or B symptoms
- No splenomegaly greater than 16 cm by a computed tomography (CT) scan
- No evidence of risk of compression of a vital organ (i.e., ureteral or epidural)
- No leukemic phase with greater than 5,000/mm^3 circulating lymphocytes
- No cytopenias, defined as any of the following:
- Platelet count less than 100,000/mm^3
- Hemoglobin less than 10 g/dL
- Absolute neutrophil count less than 1,500/mm^3
- At least 1 objective measurable disease parameter
- Abnormal positron emission tomography (PET) scans will not constitute evaluable disease unless verified by CT scan or other appropriate imaging
- Age: 18 and over
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Must meet the following criteria for labs:
- Hematopoietic
- Absolute neutrophil count at least 1,500/mm^3*
- Hemoglobin at least 10 g/dL*
- Platelet count at least 100,000/mm^3*
- NOTE: *Without growth factor and/or transfusion support
- Hepatic
- Bilirubin no greater than 2 times upper limit of normal (ULN) OR direct bilirubin normal for patients with Gilbert's Syndrome
- The aspartate transaminase (AST) and alanine transaminase (ALT) ratio (AST/ALT) no greater than 5 times ULN
- Hepatitis B surface antigen negative
- Renal
- Creatinine no greater than 2 times ULN
Who cannot join
- Evidence of transformation to a large cell histology
- Pregnant or nursing. Fertile patients must use effective contraception
- HIV positive
- Uncontrolled active infection
- Other malignancy within the past 2 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- Prior immunotherapy for lymphoma
Show all 11Show fewer
- Prior chemotherapy for lymphoma
- Concurrent chemotherapy
- Prior radiotherapy for lymphoma
- Concurrent radiotherapy
- Concurrent radioimmunotherapy
Trial locations and contacts
483 sites in 1 country.
300 sites in 1 country
United States300 sites
Oncology Services of Aberdeen
Aberdeen, South Dakota, 57401
Rosenfeld Cancer Center at Abington Memorial Hospital
Abington, Pennsylvania, 19001
Hickman Cancer Center at Bixby Medical Center
Adrian, Michigan, 49221
McDowell Cancer Center at Akron General Medical Center
Akron, Ohio, 44307
Study site
Alexandria, Minnesota, 56308
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
Allentown, Pennsylvania, 18105
Saint Anthony's Hospital at Saint Anthony's Health Center
Alton, Illinois, 62002
McFarland Clinic, PC
Ames, Iowa, 50010
AnMed Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Cancer Center
Ann Arbor, Michigan, 48106-0995
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
Langlade Memorial Hospital
Antigo, Wisconsin, 54409
Fox Valley Hematology and Oncology - East Grant Street
Appleton, Wisconsin, 54911-3496
Mission Hospitals - Memorial Campus
Asheville, North Carolina, 28801
Augusta Oncology Associates - Walton Way
Augusta, Georgia, 30901
Aurora Presbyterian Hospital
Aurora, Colorado, 80012
Rush-Copley Cancer Care Center
Aurora, Illinois, 60504
St. Agnes Hospital Cancer Center
Baltimore, Maryland, 21229
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231-2410
CancerCare of Maine at Eastern Maine Medical Center
Bangor, Maine, 04401
Pennington Cancer Center at Baton Rouge General
Baton Rouge, Louisiana, 70806
Mary Bird Perkins Cancer Center - Baton Rouge
Baton Rouge, Louisiana, 70809
Ochsner Health Center - Bluebonnet
Baton Rouge, Louisiana, 70809
St. Francis Hospital and Health Centers - Beech Grove Campus
Beech Grove, Indiana, 46107
Upper Chesapeake Medical Center
Bel Air, Maryland, 21014
Mary Rutan Hospital
Bellefontaine, Ohio, 43311
MeritCare Bemidji
Bemidji, Minnesota, 56601
Green Mountain Oncology Group
Bennington, Vermont, 05201
St. Luke's Cancer Network at St. Luke's Hospital
Bethlehem, Pennsylvania, 18015
Hematology Oncology Associates of the Quad Cities
Bettendorf, Iowa, 52722
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
St. Vincent Healthcare Cancer Care Services
Billings, Montana, 59101
Billings Clinic - Downtown
Billings, Montana, 59107-7000
Bismarck Cancer Center
Bismarck, North Dakota, 58501
Medcenter One Hospital Cancer Care Center
Bismarck, North Dakota, 58501
Mid Dakota Clinic, PC
Bismarck, North Dakota, 58501
St. Alexius Medical Center Cancer Center
Bismarck, North Dakota, 58502
St. Joseph Medical Center
Bloomington, Illinois, 61701
Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - Main Campus
Boca Raton, Florida, 33486
Mountain States Tumor Institute at St. Luke's Regional Medical Center
Boise, Idaho, 83712
Tufts-NEMC Cancer Center
Boston, Massachusetts, 02111
Boulder Community Hospital
Boulder, Colorado, 80301-9019
Wood County Oncology Center
Bowling Green, Ohio, 43402
Bozeman Deaconess Cancer Center
Bozeman, Montana, 59715
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Providence Saint Joseph Medical Center - Burbank
Burbank, California, 91505
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
St. James Healthcare Cancer Care
Butte, Montana, 59701
Graham Hospital
Canton, Illinois, 61520
Mercy Cancer Center at Mercy Medical Center
Canton, Ohio, 44708
Aultman Cancer Center at Aultman Hospital
Canton, Ohio, 44710-1799
Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital
Cape Girardeau, Missouri, 63701
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Carson Tahoe Cancer Center at Carson Tahoe Regional Medical Center
Carson City, Nevada, 89703
Memorial Hospital
Carthage, Illinois, 62321
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Blumenthal Cancer Center at Carolinas Medical Center
Charlotte, North Carolina, 28232-2861
Presbyterian Cancer Center at Presbyterian Hospital
Charlotte, North Carolina, 28233-3549
Martha Jefferson Hospital Cancer Care Center
Charlottesville, Virginia, 22901
University of Virginia Cancer Center
Charlottesville, Virginia, 22908
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, 60611-3013
John H. Stroger, Jr. Hospital of Cook County
Chicago, Illinois, 60612-3785
Resurrection Medical Center
Chicago, Illinois, 60631
Louis A. Weiss Memorial Hospital
Chicago, Illinois, 60640
Creticos Cancer Center at Advocate Illinois Masonic Medical Center
Chicago, Illinois, 60657
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Christ Hospital Cancer Center
Cincinnati, Ohio, 45219
Case Comprehensive Cancer Center
Cleveland, Ohio, 44106-5065
MetroHealth Cancer Care Center at MetroHealth Medical Center
Cleveland, Ohio, 44109
Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio, 44111
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
Finger Lakes Hematology and Oncology
Clifton Springs, New York, 14432
Penrose Cancer Center at Penrose Hospital
Colorado Springs, Colorado, 80933
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
CCOP - Columbus
Columbus, Ohio, 43215
Grant Medical Center Cancer Care
Columbus, Ohio, 43215
Mount Carmel Health - West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Batte Cancer Center at Northeast Medical Center
Concord, North Carolina, 28025
Mercy and Unity Cancer Center at Mercy Hospital
Coon Rapids, Minnesota, 55433
Geisinger Cancer Institute at Geisinger Health
Danville, Pennsylvania, 17822-0001
Danville Regional Medical Center
Danville, Virginia, 24541
Mercy Fitzgerald Hospital
Darby, Pennsylvania, 19023
Genesis Regional Cancer Center at Genesis Medical Center
Davenport, Iowa, 52803
Genesis Medical Center - West Campus
Davenport, Iowa, 52804
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
David L. Rike Cancer Center at Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
CCOP - Dayton
Dayton, Ohio, 45429
Oakwood Cancer Center at Oakwood Hospital and Medical Center
Dearborn, Michigan, 48123-2500
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526
Grady Memorial Hospital
Delaware, Ohio, 43015
St. Anthony Central Hospital
Denver, Colorado, 80204
Porter Adventist Hospital
Denver, Colorado, 80210
Presbyterian - St. Luke's Medical Center
Denver, Colorado, 80218
St. Joseph Hospital
Denver, Colorado, 80218
Rose Medical Center
Denver, Colorado, 80220
CCOP - Colorado Cancer Research Program
Denver, Colorado, 80224-2522
Mercy Capitol Hospital
Des Moines, Iowa, 50307
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa, 50314
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
John Stoddard Cancer Center at Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Delaware County Regional Cancer Center at Delaware County Memorial Hospital
Drexel Hill, Pennsylvania, 19026
Oncology Hematology Associates of Northern Pennsylvania, PC at Hahne Regional Cancer Center
DuBois, Pennsylvania, 15801
Duluth Clinic Cancer Center - Duluth
Duluth, Minnesota, 55805-1983
CCOP - Duluth
Duluth, Minnesota, 55805
Miller - Dwan Medical Center
Duluth, Minnesota, 55805
St. Luke's Hospital Cancer Care Center
Duluth, Minnesota, 55805
Veterans Affairs Medical Center - East Orange
East Orange, New Jersey, 07018-1095
Dale and Frances Hughes Cancer Center at Pocono Medical Center
East Stroudsburg, Pennsylvania, 18301
Easton Regional Cancer Center at Easton Hospital
Easton, Pennsylvania, 18042
Center for Cancer Treatment & Prevention at Sacred Heart Hospital
Eau Claire, Wisconsin, 54701
Marshfield Clinic Cancer Care at Regional Cancer Center
Eau Claire, Wisconsin, 54701
Fairview Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Elkhart General Hospital
Elkhart, Indiana, 46515
Vince Lombardi Cancer Center at Aurora Lakeland Medical Center - Elkhorn
Elkhorn, Wisconsin, 53121
Union Hospital Cancer Program at Union Hospital
Elkton, Maryland, 21921
Elmhurst Memorial Hospital
Elmhurst, Illinois, 60126
Swedish Medical Center
Englewood, Colorado, 80110
Dizzy Gillespie Cancer Institute at Englewood Hospital and Medical Center
Englewood, New Jersey, 07631
Ephrata Cancer Center at Ephrata Community Hospital
Ephrata, Pennsylvania, 17522
Green Bay Oncology, Limited - Escanaba
Escanaba, Michigan, 49431
Eureka Community Hospital
Eureka, Illinois, 61530
Evanston Northwestern Healthcare - Evanston Hospital
Evanston, Illinois, 60201-1781
St. Francis Hospital
Evanston, Illinois, 60202
Kaiser Permanente Medical Center - Fair Oaks
Fairfax, Virginia, 22033
North Bay Cancer Center
Fairfield, California, 94533
CCOP - MeritCare Hospital
Fargo, North Dakota, 58122
MeritCare Broadway
Fargo, North Dakota, 58122
St. Francis Hospital
Federal Way, Washington, 98003
Study site
Fergus Falls, Minnesota, 56537
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
McLeod Regional Medical Center
Florence, South Carolina, 29501
Central Wisconsin Cancer Program at Agnesian HealthCare
Fond du Lac, Wisconsin, 54935
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Front Range Cancer Specialists
Fort Collins, Colorado, 80528
Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
Fort Smith, Arkansas, 72903
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, 46815
Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Frederick Memorial Hospital Regional Cancer Therapy Center
Frederick, Maryland, 21701
Fredericksburg Oncology, Incorporated
Fredericksburg, Virginia, 22401
Kaiser Permanente - Fremont
Fremont, California, 94538
Mercy and Unity Cancer Center at Unity Hospital
Fridley, Minnesota, 55432
University of Florida Shands Cancer Center
Gainesville, Florida, 32610-0232
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
Galesburg Clinic, PC
Galesburg, Illinois, 61401
Galesburg Cottage Hospital
Galesburg, Illinois, 61401
Delnor Community Hospital - Geneva
Geneva, Illinois, 60134
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
Center for Cancer Care at Goshen General Hospital
Goshen, Indiana, 46526
Altru Cancer Center at Altru Hospital
Grand Forks, North Dakota, 58201
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
Grand Junction, Colorado, 81502
Big Sky Oncology
Great Falls, Montana, 59405-5309
Great Falls Clinic - Main Facility
Great Falls, Montana, 59405
Sletten Cancer Institute at Benefis Healthcare
Great Falls, Montana, 59405
Study site
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54301-3526
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
St. Mary's Hospital Medical Center - Green Bay
Green Bay, Wisconsin, 54303
St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54307-3508
Vince Lombardi Cancer Clinic - Green Bay at Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311
Leo W. Jenkins Cancer Center at ECU Medical School
Greenville, North Carolina, 27835-6028
CCOP - Greenville
Greenville, South Carolina, 29615
Van Elslander Cancer Center at St. John Hospital and Medical Center
Grosse Pointe Woods, Michigan, 48236
Ingalls Cancer Care Center at Ingalls Memorial Hospital
Harvey, Illinois, 60426
Hattiesburg Clinic, PA at Forrest General
Hattiesburg, Mississippi, 39401
Hematology & Oncology Clinic
Hattiesburg, Mississippi, 39402
Mason District Hospital
Havana, Illinois, 62644
Kaiser Permanente Medical Center - Hayward
Hayward, California, 94545
St. Peter's Hospital
Helena, Montana, 59601
Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
Penn State Cancer Institute at Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
Hinsdale Hematology Oncology Associates
Hinsdale, Illinois, 60521
Memorial Cancer Institute at Memorial Regional Hospital
Hollywood, Florida, 33021
Hopedale Medical Complex
Hopedale, Illinois, 61747
Terrebonne General Medical Center
Houma, Louisiana, 70360
Edwards Comprehensive Cancer Center at Cabell Huntington Hospital
Huntington, West Virginia, 25701
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Independence Regional Health Center
Independence, Missouri, 64050
Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio, 44131
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202-5289
Veterans Affairs Medical Center - Indianapolis
Indianapolis, Indiana, 46202
William N. Wishard Memorial Hospital
Indianapolis, Indiana, 46202
Dickinson County Healthcare System
Iron Mountain, Michigan, 49801
Foote Memorial Hospital
Jackson, Michigan, 49201
Baptist Cancer Institute - Jacksonville
Jacksonville, Florida, 32207
Mayo Clinic - Jacksonville
Jacksonville, Florida, 32224
Joliet Oncology-Hematology Associates, Limited - West
Joliet, Illinois, 60435
Ella Milbank Foshay Cancer Center at Jupiter Medical Center
Jupiter, Florida, 33458
Borgess Medical Center
Kalamazoo, Michigan, 49001
West Michigan Cancer Center
Kalamazoo, Michigan, 49007-3731
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Glacier Oncology, PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology at KRMC
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Provena St. Mary's Regional Cancer Center - Kankakee
Kankakee, Illinois, 60901
Providence Medical Center
Kansas City, Kansas, 66112
Truman Medical Center - Hospital Hill
Kansas City, Missouri, 64108
Saint Luke's Cancer Institute at Saint Luke's Hospital
Kansas City, Missouri, 64111
Kansas City Cancer Center at St. Joseph's Medical Mall
Kansas City, Missouri, 64114
St. Joseph Medical Center
Kansas City, Missouri, 64114
North Kansas City Hospital
Kansas City, Missouri, 64116
Parvin Radiation Oncology
Kansas City, Missouri, 64116
CCOP - Kansas City
Kansas City, Missouri, 64131
Radiation Oncology Associates of Kansas City at Northland Radiation Oncology Center
Kansas City, Missouri, 64154
Good Samaritan Cancer Center at Good Samaritan Hospital
Kearney, Nebraska, 68848-1990
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Kinston Medical Specialists
Kinston, North Carolina, 28501
Richard G. Laube Cancer Center at ACMH
Kittanning, Pennsylvania, 16201
Howard Community Hospital
Kokomo, Indiana, 46904
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
La Grange Memorial Hospital
La Grange, Illinois, 60525
Center for Cancer Therapy at LaPorte Hospital and Health Services
La Porte, Indiana, 46350
Clarian Arnett Cancer Care
Lafayette, Indiana, 47904
Haematology-Oncology Associates of Ohio and Michigan, PC
Lambertville, Michigan, 48144
Fairfield Medical Center
Lancaster, Ohio, 43130
Lancaster General Hospital
Lancaster, Pennsylvania, 17604
Sparrow Regional Cancer Center
Lansing, Michigan, 48912-1811
Kaiser Permanente Mid-Atlantic Medical Group-Largo Medical Facility
Largo, Maryland, 20774
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
CCOP - Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Central Pennsylvania Hematology and Medical Oncology Associates, PC
Lemoyne, Pennsylvania, 17043
Tunnell Cancer Center at Beebe Medical Center
Lewes, Delaware, 19958
Lewistown Hospital
Lewistown, Pennsylvania, 17044
Southwest Medical Center
Liberal, Kansas, 67901
St. Rita's Medical Center
Lima, Ohio, 45801
Lima Memorial Hospital
Lima, Ohio, 45804
Cancer Resource Center - Lincoln
Lincoln, Nebraska, 68510
Meeker County Memorial Hospital
Litchfield, Minnesota, 55355
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Hope Cancer Care Center at Longmont United Hospital
Longmont, Colorado, 80502
McKee Medical Center
Loveland, Colorado, 80539
Kaiser Permanente - Towson
Lutherville, Maryland, 21093
McDonough District Hospital
Macomb, Illinois, 61455
Medical Center of Central Georgia
Macon, Georgia, 31208
Dean Medical Center - Madison
Madison, Wisconsin, 53717
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
Madison, Wisconsin, 53792-6164
Holy Family Memorial Medical Center Cancer Care Center
Manitowoc, Wisconsin, 54221-1450
HealthEast Cancer Care at St. John's Hospital
Maplewood, Minnesota, 55109
Minnesota Oncology Hematology, PA - Maplewood
Maplewood, Minnesota, 55109
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Bay Area Cancer Care Center at Bay Area Medical Center
Marinette, Wisconsin, 54143
Marshfield Clinic - Marshfield Center
Marshfield, Wisconsin, 54449
Saint Joseph's Hospital
Marshfield, Wisconsin, 54449
Mercy Cancer Center at Mercy Medical Center - North Iowa
Mason City, Iowa, 50401
Northwest Ohio Oncology Center
Maumee, Ohio, 43537
St. Luke's Hospital
Maumee, Ohio, 43537
Riddle Memorial Hospital Cancer Center
Media, Pennsylvania, 19063
CCOP - Mount Sinai Medical Center
Miami Beach, Florida, 33140
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Aurora Sinai Medical Center
Milwaukee, Wisconsin, 53201-0342
Medical Consultants, Limited
Milwaukee, Wisconsin, 53215
Froedtert Hospital and Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, 53226
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Marshfield Clinic - Lakeland Center
Minocqua, Wisconsin, 54548
Trinity CancerCare Center
Minot, North Dakota, 58701
Community Medical Center
Missoula, Montana, 59801
Guardian Oncology and Center for Wellness
Missoula, Montana, 59804
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59807-7877
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59807
Memorial Medical Center
Modesto, California, 95355
Community Cancer Center of Monroe
Monroe, Michigan, 48162
Mercy Memorial Hospital - Monroe
Monroe, Michigan, 48162
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Hematology Oncology Consultants - Naperville
Naperville, Illinois, 60540
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, 70112
Medical Center of Louisiana - New Orleans
New Orleans, Louisiana, 70112
CCOP - Ochsner
New Orleans, Louisiana, 70121
Ochsner Cancer Institute at Ochsner Clinic Foundation
New Orleans, Louisiana, 70121
CCOP - Christiana Care Health Services
Newark, Delaware, 19713
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Cancer Center of Kansas, PA - Newton
Newton, Kansas, 67114
BroMenn Regional Medical Center
Normal, Illinois, 61761
Community Cancer Center
Normal, Illinois, 61761
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut, 06360
Kaiser Permanente Medical Center - Oakland
Oakland, California, 94611
Green Bay Oncology, Limited - Oconto Falls
Oconto Falls, Wisconsin, 54154
Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields
Olympia Fields, Illinois, 60461
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
Methodist Estabrook Cancer Center
Omaha, Nebraska, 68114
About this study
Official title: Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens For Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known which rituximab regimen is more effective in treating indolent non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is studying two different schedules of rituximab and comparing them to see how well they work in treating patients with low tumor burden indolent stage III non-Hodgkin's lymphoma or stage IV non-Hodgkin's lymphoma.
Read the detailed description
OBJECTIVES:
Primary
- To compare time to rituximab failure between the rituximab scheduled and rituximab retreatment arms.
Secondary
- To compare the time to first cytotoxic therapy between the rituximab scheduled and rituximab retreatment arms.
- To document the rationale for beginning cytotoxic therapy; defined as chemotherapy, radiation therapy or radioimmunotherapy.
- To compare the toxicities associated with rituximab therapy between the two randomized treatment arms.
- Quality of Life Objectives:
- To compare health-related quality of life, distress, psychological functioning, physical well-being and functional well-being of patients receiving rituximab scheduled to those receiving rituximab retreatment.
- To examine the impact of differential treatment response (delayed time to rituximab failure and/or time to first cytotoxic therapy), if observed, on quality of life, distress, and psychological functioning on patients receiving rituximab scheduled to those receiving rituximab retreatment.
- To obtain prospective data on physical and functional well-being during treatment with rituximab.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to histologic subtype (follicular vs other), age (under 60 vs 60 and over), and the time from diagnosis (less than 1 year vs at least 1 year).
- Induction rituximab: Patients receive rituximab Intravenous (IV) once a week for 4 weeks.
Patients are re-evaluated 9 weeks after the completion of induction rituximab. Patients with a partial or complete response to induction rituximab are randomized to 1 of 2 treatment arms.
- Arm A (retreatment rituximab): Patients receive rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months.
- Arm B (scheduled rituximab): Patients receive a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity.
Quality of life is assessed after induction rituximab treatment and at 26, 39, 65, 117, 169, and 221 weeks after randomization.
Patients are followed at least annually for 15 years from study entry.
- Conditions
- Lymphoma
- Being tested
- rituximab
- Keywords
- stage III grade 1 follicular lymphoma, stage III grade 2 follicular lymphoma, stage IV grade 1 follicular lymphoma, stage IV grade 2 follicular lymphoma, stage III small lymphocytic lymphoma, stage III marginal zone lymphoma, stage IV small lymphocytic lymphoma, stage IV marginal zone lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma
- Medical subject headings
- Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
rituximabBiological
Given IV
| Study group | Role | What they receive |
|---|---|---|
| Arm A: Rituximab Retreatment | Active comparator | Patients receive rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months. Receives: Biological: rituximab |
| Arm B: Rituximab Scheduled | Experimental | Patients receive a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity. Receives: Biological: rituximab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to Rituximab Failure (TTRF)
TTRF is defined as the time from randomization until any one of the following criteria are met, and censored at last disease assessment for cases who have not experienced failure (with the cut-off date for final analysis of 11/1/2011): 1. No response (partial response (PR) or complete response (CR)) to rituximab retreatment (Arm A treatment). 2. Time to progression < 26 weeks from day 1 of most recent rituximab treatment. 3. Initiation of alternative therapy. 4. Inability to complete protocol therapy (due to adverse events, patient preference, or any other reason, including death).
Measured: Assessed (by restaging CT scans) 26 weeks ± 2 weeks from each rituximab treatment (including induction), counting the first rituximab dose as Day 1, until rituximab failure observed or July 17, 2013, whichever occurred first.
Secondary outcomes (2)
Time to First Cytotoxic Therapy (TTFC)
TTFC is defined as the time from randomization to the time of first cytotoxic therapy (chemo and radio therapy), and censored as last follow-up time if no cytotoxic therapy has been used. Since median TTFC was not reached in 3 out of the 4 groups, 3-year TTFC was reported which was defined as the probability of not starting first cytotoxic therapy at 3 years.
Measured: Assessed every 13 weeks until rituximab failure observed or August 2013, whichever occurred first.
Overall Health-related Quality of Life (HRQL) at 6 Month After Randomization
The overall HRQL was measured by the change in Functional Assessment of Cancer Therapy - General (FACT-G) from baseline to 6 months after randomization. The FACT-G is a 27-item assessment used to measure HRQL, specifically, physical, functional, social and emotional well-being. The total score ranges from 0 to 108, with higher scores indicating better HRQL.
Measured: Assessed at baseline and 6 months after randomization.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jan 2004 (estimated)
- Study start23 Jan 2004
- Primary completionSep 2013
- Study completionAug 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for LymphomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 545 participants (actual)
Sponsor and investigators
- Lead sponsor
- Eastern Cooperative Oncology Group
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Brad S. Kahl, MD, Study chair, University of Wisconsin, Madison
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00075946
- Sponsor's protocol ID
- CDR0000346359
- Other IDs
- U10CA021115, ECOG-E4402
- Status last verified
- Jan 2024
- First submitted
- 12 Jan 2004
- Last updated
- 1 Feb 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Kahl BS, Williams ME, Hong F, et al.: Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group Protocol E4402: rituximab extended schedule or re-treatment trial (RESORT) . [Abstract] Blood 110 (11): A-3420, 2007.
Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014 Oct 1;32(28):3096-102. doi: 10.1200/JCO.2014.56.5853. Epub 2014 Aug 25.
PubMed 25154829Rutherford SC, Yin J, Pederson L, Perez Burbano G, LaPlant B, Shadman M, Li H, LeBlanc ML, Kenkre VP, Hong F, Blum KA, Dockter T, Martin P, Jung SH, Grant B, Rosenbaum C, Ujjani C, Barr PM, Unger JM, Cheson BD, Bartlett NL, Kahl B, Friedberg JW, Mandrekar SJ, Leonard JP. Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. J Clin Oncol. 2023 Jan 10;41(2):336-342. doi: 10.1200/JCO.21.02301. Epub 2022 Jul 5.
PubMed 35787017
Study at a glance
From the registry record, last updated by the sponsor on 1 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens For Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
- ClinicalTrials.gov ID
- NCT00075946
- Acronym / sponsor ID
- CDR0000346359
- Conditions
- Lymphoma
- Keywords
- stage III grade 1 follicular lymphoma, stage III grade 2 follicular lymphoma, stage IV grade 1 follicular lymphoma, stage IV grade 2 follicular lymphoma, stage III small lymphocytic lymphoma, stage III marginal zone lymphoma, stage IV small lymphocytic lymphoma, stage IV marginal zone lymphoma
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 545 participants (actual)
- Lead sponsor
- Eastern Cooperative Oncology GroupResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 23 Jan 2004 (actual)
- Primary completion
- Sep 2013 (actual)
- Study completion
- Aug 2021 (actual)
- First posted
- 14 Jan 2004 (estimated)
- Results
- Posted 22 Jun 2015
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known which rituximab regimen is more effective in treating indolent non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is studying two different schedules of rituximab and comparing them to see how well they work in treating patients with low tumor burden indolent stage III non-Hodgkin's lymphoma or stage IV non-Hodgkin's lymphoma.
Detailed description
OBJECTIVES:
Primary
- To compare time to rituximab failure between the rituximab scheduled and rituximab retreatment arms.
Secondary
- To compare the time to first cytotoxic therapy between the rituximab scheduled and rituximab retreatment arms.
- To document the rationale for beginning cytotoxic therapy; defined as chemotherapy, radiation therapy or radioimmunotherapy.
- To compare the toxicities associated with rituximab therapy between the two randomized treatment arms.
- Quality of Life Objectives:
- To compare health-related quality of life, distress, psychological functioning, physical well-being and functional well-being of patients receiving rituximab scheduled to those receiving rituximab retreatment.
- To examine the impact of differential treatment response (delayed time to rituximab failure and/or time to first cytotoxic therapy), if observed, on quality of life, distress, and psychological functioning on patients receiving rituximab scheduled to those receiving rituximab retreatment.
- To obtain prospective data on physical and functional well-being during treatment with rituximab.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to histologic subtype (follicular vs other), age (under 60 vs 60 and over), and the time from diagnosis (less than 1 year vs at least 1 year).
- Induction rituximab: Patients receive rituximab Intravenous (IV) once a week for 4 weeks.
Patients are re-evaluated 9 weeks after the completion of induction rituximab. Patients with a partial or complete response to induction rituximab are randomized to 1 of 2 treatment arms.
- Arm A (retreatment rituximab): Patients receive rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months.
- Arm B (scheduled rituximab): Patients receive a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity.
Quality of life is assessed after induction rituximab treatment and at 26, 39, 65, 117, 169, and 221 weeks after randomization.
Patients are followed at least annually for 15 years from study entry.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm A: Rituximab Retreatment | Active comparator | Biological: rituximabPatients receive rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months. |
| Arm B: Rituximab Scheduled | Experimental | Biological: rituximabPatients receive a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (34 listed)
- Histologically confirmed non-Hodgkin's lymphoma, including 1 of the following:
- Stage III or IV disease
- Must meet the following criteria for low tumor burden:
- At least 1 objective measurable disease parameter
- Age: 18 and over
Key exclusion criteria (11 listed)
- Evidence of transformation to a large cell histology
- Pregnant or nursing. Fertile patients must use effective contraception
- HIV positive
- Uncontrolled active infection
- Other malignancy within the past 2 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| rituximabGiven IV | Biological | Arm A: Rituximab Retreatment, Arm B: Rituximab Scheduled |
Primary outcome
Time to Rituximab Failure (TTRF)
Time frame: Assessed (by restaging CT scans) 26 weeks ± 2 weeks from each rituximab treatment (including induction), counting the first rituximab dose as Day 1, until rituximab failure observed or July 17, 2013, whichever occurred first.
TTRF is defined as the time from randomization until any one of the following criteria are met, and censored at last disease assessment for cases who have not experienced failure (with the cut-off date for final analysis of 11/1/2011): 1. No response (partial response (PR) or complete response (CR)) to rituximab retreatment (Arm A treatment). 2. Time to progression < 26 weeks from day 1 of most recent rituximab treatment. 3. Initiation of alternative therapy. 4. Inability to complete protocol therapy (due to adverse events, patient preference, or any other reason, including death).
2 secondary outcomes
Time to First Cytotoxic Therapy (TTFC)
Time frame: Assessed every 13 weeks until rituximab failure observed or August 2013, whichever occurred first.
Overall Health-related Quality of Life (HRQL) at 6 Month After Randomization
Time frame: Assessed at baseline and 6 months after randomization.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Feb 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publicationKahl BS, Williams ME, Hong F, et al.: Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group Protocol E4402: rituximab extended schedule or re-treatment trial (RESORT) . [Abstract] Blood 110 (11): A-3420, 2007.
- Results publication: PubMed 25154829Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014 Oct 1;32(28):3096-102. doi: 10.1200/JCO.2014.56.5853. Epub 2014 Aug 25.
- Derived from this study: PubMed 35787017Rutherford SC, Yin J, Pederson L, Perez Burbano G, LaPlant B, Shadman M, Li H, LeBlanc ML, Kenkre VP, Hong F, Blum KA, Dockter T, Martin P, Jung SH, Grant B, Rosenbaum C, Ujjani C, Barr PM, Unger JM, Cheson BD, Bartlett NL, Kahl B, Friedberg JW, Mandrekar SJ, Leonard JP. Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. J Clin Oncol. 2023 Jan 10;41(2):336-342. doi: 10.1200/JCO.21.02301. Epub 2022 Jul 5.
Related trials for Lymphoma
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RecruitingPhase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Non-hodgkin Lymphoma
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
Not yet recruitingPhase 1
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma
Active, not recruitingPhase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Brad S. Kahl, MD study chair
University of Wisconsin, Madison
483 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing rituximab in people with Lymphoma, run by Eastern Cooperative Oncology Group at 483 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 34 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 483 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Jun 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to Rituximab Failure (TTRF) (time frame: Assessed (by restaging CT scans) 26 weeks ± 2 weeks from each rituximab treatment (including induction), counting the first rituximab dose as Day 1, until rituximab failure observed or July 17, 2013, whichever occurred first.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00075946, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Feb 2024.